PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 28, 2026Expert Review of Pharmacoeconomics & Outcomes Research0 citations

Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB–IIC melanoma in the United States

View Full Paper
IEIslam EljilanyVDVakaramoko Diaby

Key Points

  • This analysis estimates the cost-effectiveness of adjuvant nivolumab in patients with resected stage IIB–IIC melanoma.
  • Utilized a conservative recurrence-focused framework for evaluation.
  • Assessed health outcomes against costs of nivolumab treatment over a short-term horizon.
  • Nivolumab improves health outcomes but is unlikely to be cost-effective at current prices.

Abstract

Within a conservative recurrence-focused framework, adjuvant nivolumab improves health outcomes but is unlikely to be cost-effective at current prices over a short-term horizon. Reassessment will be essential as longer-term evidence emerges.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Eljilany et al. (2026) studied this question.

synapsesocial.com/papers/69f04e08727298f751e71fdahttps://doi.org/10.1080/14737167.2026.2665725
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma2026
  2. 2Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma2024 · 504 citations
  3. 3Adjuvant immunotherapy in high-risk resectable melanoma: A real-world experience2024
  4. 4Perioperative immunotherapy for advanced resectable melanoma: a cost-effectiveness analysis2026
  5. 5Cost-saving analysis of neoadjuvant versus adjuvant immunotherapy in clinical stage III melanoma: A real-world Brazilian perspective.2026